New ultrasound technique could replace needle biopsy for liver patients

NCT ID NCT06513195

Recruiting now Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special ultrasound done through an endoscope can measure how well beta-blockers are working in people with cirrhosis and high blood pressure in the liver. Twenty-four participants will get the ultrasound before and after three months of treatment with carvedilol. The goal is to see if this less invasive method matches the standard pressure measurement done through a vein in the neck.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carvedilol (a non-selective beta-blocker)
What this could lead to: If successful, this could provide a less invasive way to monitor treatment response in cirrhosis patients with portal hypertension.
What could go wrong: This is a small, early-phase study with only 24 participants. The procedure is still experimental and may not replace standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PORTAL HYPERTENSION RELATED TO CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PORTAL HYPERTENSION RELATED TO CIRRHOSIS

Contacts and locations

Locations

University Hospital Leuven
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.